Companies Dominating the Advanced Therapy Medicinal Products Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Takeda Pharmaceutical Company Limited
- Gilead Sciences, Inc.
- Bluebird Bio, Inc.
- BioMarin Pharmaceuticals Inc.
- Vericel Corporation
- Mallinckrodt Pharmaceuticals
- UniQure N.V.
- JCR Pharmaceuticals Co., Ltd.
- Spark Therapeutics, Inc.
- Kolon TissueGene,Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Advanced Therapy Medicinal Products Market in 2025 is assessed at USD 14.65 billion.
The global market size was worth more than USD 13.21 billion in 2024 and is poised to witness a CAGR of over 13.6%, crossing USD 69.31 billion revenue by 2037.
North America is likely to achieve USD 30.5 billion by 2037, attributed to higher cases of cancer and neurological disorders, along with significant investment by private companies for the development of advanced therapy medicinal products.
The major players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.
